GenoSaber Biotech Co.Ltd. - Circulating Tumor Cell Detection Pioneer

admin12026-04-18 09:26:05

📢 Important Milestones (2025-2026):
In December 2025, GenoSaber Biotech was recognized by jiangsu Economic Daily as one of the high-quality biomedical enterprises driving the booming biopharmaceutical industry in Nantong Economic and Technological Development Zone. The company continues to be listed among key players in the global CTC Detection Market and Tumor Detection Kit Market alongside international leaders such as Bio-Rad, Roche, Qiagen, and BGI Genomics.

Company Overview (Updated April 2026)

GenoSaber Biotech Co.Ltd. (Chinese: 江苏格诺生物科技集团有限公司) is a biotechnology company specializing in circulating tumor cell (CTC) detection and liquid biopsy technologies. Established in 2011 with headquarters and manufacturing in Nantong, Jiangsu Province, China, and R&D operations in Shanghai, GenoSaber is recognized as a pioneer in china's liquid biopsy industry and a key contributor to the global CTC detection market.

Mission: To advance non-invasive cancer diagnostics through innovative CTC detection technologies, enabling earlier cancer detection, precise treatment monitoring, and improved patient outcomes.

Corporate History and Regulatory Milestones

Founding and Early Development (2011-2016)

- 2011: Company established in Nantong, Jiangsu Province, China

- January 11, 2016: Received landmark approval from the China Food and Drug Administration (CFDA, now NMPA) for CytoploRare® Folate Receptor-Positive Circulating Tumor Cell Detection Kit (Registration No. 国械注准20163400061)

- Significance: This was the first lung cancer CTC detection kit approved in China and the first of its kind globally for lung cancer diagnosis using ligand-targeted PCR technology

Regulatory Certifications

- NMPA (China): Class III medical device approval (国械注准20163400061) for lung cancer CTC detection

- CE Mark (European Union): Obtained EU CE certification for IVD products

- Unified Social Credit Code: 913206915810046585

Core Technology and Products

CytoploRare® FR+CTC Detection Kit

The company's flagship product is the CytoploRare® Folate Receptor-Positive Circulating Tumor Cell Detection Kit, based on proprietary ligand-targeted PCR technology:

Technology Principle:

- Two-step process: (1) CTC negative enrichment through immunomagnetic beads to deplete leUKocytes and erythrocytes; (2) CTC quantification by ligand-targeted polymerase chain reaction (PCR)

- Uses a proprietary probe consisting of conjugates of folic acid (or folic acid analog) and a synthesized oligonucleotide that specifically binds to folate receptor-alpha (FRα) highly expressed on tumor cells

- Signal amplification through receptor-ligand binding and PCR enables detection of rare CTCs with approximately 10^12-fold signal amplification

- Quantitative detection range: 2 to 2×10^5 CTC units per 3 mL blood

Clinical Applications (NMPA Approved):

- Auxiliary diagnosis for suspected lung cancer patients not yet diagnosed

- Monitoring disease progression and treatment efficacy in non-small cell lung cancer (NSCLC) patients undergoing surgery or platinum-based chemotherapy

- Supplementary diagnostic tool when CT scans reveal pulmonary nodules of uncertain malignancy

Product Specifications

- Sample Volume: 3 mL whole blood collected in EDTA anticoagulant tubes

- Analysis Time: Samples analyzed within 12-24 hours of collection

- Detection Platform: ABI 7300/7500/StepOne real-time PCR systems (Thermo Fisher)

- Kit Components: Red cell lysis buffer, anti-CD45 immunomagnetic beads, anti-CD14 beads, folate-oligonucleotide probe, wash buffer, stripping buffer, neutralization buffer, PCR standards, and quality controls

Clinical Evidence and Research

The CytoploRare® kit has been widely validated in peer-reviewed clinical studies conducted at leading Chinese hospitals:

Published Clinical Studies Include:

- Non-Small Cell Lung Cancer (NSCLC): Multiple studies demonstrating correlation between FR+CTC levels and tumor stage, with CTC counts increasing along with tumor progression

- Small Cell Lung Cancer (SCLC): Diagnostic and efficacy evaluation studies showing clinical utility

- Prostate Cancer: Study at China-Japan Friendship Hospital showing FR+CTC as potential diagnostic biomarker

- Breast Cancer: Research demonstrating FR+CTC value for diagnosis, prognostication, and therapeutic monitoring

- Elderly Cancer Patients: Clinical trial at China-Japan Friendship Hospital (September 2017-June 2018) enrolling subjects aged 80-110 years

- Pemetrexed-Based Chemotherapy Monitoring: Prospective phase II clinical trial at Shanghai Pulmonary Hospital for advanced non-squamous NSCLC

Meta-Analysis Evidence:

- Systematic review and meta-analysis of 11 studies (3,469 subjects) published in 2023 confirmed FR+CTC as valuable diagnostic biomarker for lung cancer

- All Included studies used CytoploRare reagent for FR+CTC detection

Market Position and Competitive Landscape

GenoSaber Biotech is recognized as a key player in the global CTC detection and tumor detection kit markets:

- CTC Detection Market: Listed alongside Bio-Rad, Roche, Biocartis, Qiagen, Guardant Health, Johnson & Johnson, NeoGenomics, Guangzhou Wondfo Biotech, and BGI Genomics

- Tumor Detection Kit Market: Recognized competitor alongside Abbott Laboratories, Thermo Fisher Scientific, Amoy Diagnostics, HaploX, Burning Rock Biotech, and YZY Biopharma

- China Market Position: One of the first domestic companies to receive NMPA approval for liquid biopsy products, contributing to the acceleration of China's liquid biopsy industry since 2016

Regional Development and Industry Recognition (2025-2026)

- Nantong Economic and Technological Development Zone: In December 2025, GenoSaber was highlighted by Jiangsu Economic Daily as one of the quality biomedical enterprises driving the region's booming biopharmaceutical industry, alongside companies such as Merck, Shengshi Bio, and Lude Medical

- The company contributes to Nantong's "3+1" leading industrial system focusing on next-generation information technology, high-end equipment, medical health, and new energy